Literature DB >> 6749189

Role of the parasympathetic system in airway obstruction due to emphysema.

N J Gross, M S Skorodin.   

Abstract

To study the relative contributions of parasympathetic and sympathetic mechanisms in airway obstruction in patients with emphysema, we gave supramaximal doses of anticholinergic and adrenergic agents in sequence and in combination. Serial doses of one agent were administered to achieve a plateau of bronchodilatation; after that the other agent was administered. The plateau achieved with the anticholinergic agent (atropine methonitrate) was significantly higher than that achieved with the adrenergic agent (salbutamol). When the adrenergic agent was given first, additional bronchodilatation was achieved with subsequent use of the anticholinergic agent. When the anticholinergic agent was given first, no additional bronchodilatation was achieved with subsequent administration of the adrenergic agent. When both agents were given simultaneously, the degree of bronchodilatation was virtually identical to that obtained with the anticholinergic agent alone. Tests sensitive to small-airway and large-airway function and lung volumes gave essentially the same results. Thus, all achievable bronchodilatation was obtained with the anticholinergic agent alone. These results suggest that the two classes of agents produce bronchodilatation through a common cholinergic pathway in emphysema, and support the concept that parasympathetic activity is the dominant reversible component of airway obstruction in this disease.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6749189     DOI: 10.1056/NEJM198408163110701

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  36 in total

1.  Regional quantification of muscarinic acetylcholine receptors and β-adrenoceptors in human airways.

Authors:  T Ikeda; A S M Anisuzzaman; H Yoshiki; M Sasaki; T Koshiji; J Uwada; A Nishimune; H Itoh; I Muramatsu
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

Review 2.  G Protein-Coupled Receptors in Asthma Therapy: Pharmacology and Drug Action.

Authors:  Stacy Gelhaus Wendell; Hao Fan; Cheng Zhang
Journal:  Pharmacol Rev       Date:  2020-01       Impact factor: 25.468

3.  Safety and Dose Study of Targeted Lung Denervation in Moderate/Severe COPD Patients.

Authors:  Arschang Valipour; Pallav L Shah; Christophe Pison; Vincent Ninane; Wim Janssens; Thierry Perez; Romain Kessler; Gaetan Deslee; Justin Garner; Christine Abele; Jorine E Hartman; Dirk-Jan Slebos
Journal:  Respiration       Date:  2019-06-20       Impact factor: 3.580

Review 4.  The bronchoscopic interventions for chronic obstructive pulmonary disease according to different phenotypes.

Authors:  Jian-Jun Zhang; Yan Yin; Gang Hou
Journal:  J Thorac Dis       Date:  2017-05       Impact factor: 2.895

5.  Internal medicine: use of ipratropium bromide in chronic obstructive pulmonary disease.

Authors:  D P Tashkin
Journal:  West J Med       Date:  1987-09

6.  Emergency use of nebulised bronchodilator drugs in British hospitals.

Authors:  B R O'Driscoll; G M Cochrane
Journal:  Thorax       Date:  1987-07       Impact factor: 9.139

Review 7.  Role of epithelial sodium channels in the regulation of lung fluid homeostasis.

Authors:  Sadis Matalon; Rafal Bartoszewski; James F Collawn
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-10-02       Impact factor: 5.464

8.  Pharmacological assessment of the duration of action of glycopyrrolate vs tiotropium and ipratropium in guinea-pig and human airways.

Authors:  Gino Villetti; Marco Bergamaschi; Franco Bassani; Pier Tonino Bolzoni; Selena Harrison; Paolo M Gigli; Alberto Janni; Pierangelo Geppetti; Maurizio Civelli; Riccardo Patacchini
Journal:  Br J Pharmacol       Date:  2006-06       Impact factor: 8.739

Review 9.  Crosstalk between beta-2-adrenoceptor and muscarinic acetylcholine receptors in the airway.

Authors:  Tonio Pera; Raymond B Penn
Journal:  Curr Opin Pharmacol       Date:  2014-04-17       Impact factor: 5.547

Review 10.  Safety, tolerability and risk benefit analysis of tiotropium in COPD.

Authors:  Yuji Oba; Tareq Zaza; Danish M Thameem
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.